Samsung Bioepis has become the latest biosimilars developer to kick off Phase III trials for a rival to Janssen’s Stelara (ustekinumab) blockbuster treatment for Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis, with the Korean firm’s SB17 candidate beginning a study in plaque psoriasis patients.
Samsung Bioepis Is Latest To Move Ustekinumab Into Phase III
Joins A Slew Of Other Biosimilar Developers Jostling For Position On Stelara
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
